| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3466718 | European Journal of Internal Medicine | 2014 | 5 Pages |
•ESRD patients with secondary HPT had a 10.1-fold risk of thyroid cancer than those ESRD without HPT.•Physicians should keep alert for occult thyroid cancer in ESRD patients with secondary HPT.•Thyroid sonography in ESRD patients with secondary or tertiary HPT is suggested.
ObjectivesWe conducted a retrospective cohort study to investigate the risk of cancer in end stage renal disease (ESRD) patients with secondary hyperparathyroidism (HPT).Patients and methodsThis study investigated the elevated overall cancer risk in ESRD patients with secondary HPT in Taiwan. We used a population-based retrospective cohort consisting of original claims data of 1 million beneficiaries randomly sampled from the Taiwan National Health Insurance Research Database (NHIRD). We calculated the hazard ratios (HRs) and 95% confidence intervals (CIs) of cancer in the ESRD with secondary HPT and comparison cohorts, using the Cox proportional hazards regression model.ResultsWe observed that ESRD patients with secondary HPT exhibited a 10.1-fold increased risk of thyroid cancer than did ESRD patients without this parathyroid complication, after adjusting for comorbidities (95% confidence interval = 1.12–91.0).ConclusionThese phenomena indicate that ESRD patients with secondary HPT are at greater risk of thyroid cancer. Physicians should be alert for occult thyroid cancer in ESRD patients with secondary HPT.
